LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 192

Search options

  1. Article ; Online: Novel immunotherapeutic combinations moving forward: the modulation of the immunosuppressive microenvironment.

    Andersen, Mads Hald

    Seminars in immunopathology

    2023  Volume 45, Issue 2, Page(s) 159–161

    MeSH term(s) Humans ; Immunosuppressive Agents ; Immunotherapy ; Tumor Microenvironment
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2023-04-20
    Publishing country Germany
    Document type Editorial
    ZDB-ID 2316828-6
    ISSN 1863-2300 ; 1863-2297
    ISSN (online) 1863-2300
    ISSN 1863-2297
    DOI 10.1007/s00281-023-00991-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1425: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Novel immune modulatory vaccines targeting TGFβ.

    Andersen, Mads Hald

    Cellular & molecular immunology

    2023  Volume 20, Issue 5, Page(s) 551–553

    MeSH term(s) Transforming Growth Factor beta ; Vaccines ; Signal Transduction
    Chemical Substances Transforming Growth Factor beta ; Vaccines
    Language English
    Publishing date 2023-03-27
    Publishing country China
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 2435097-7
    ISSN 2042-0226 ; 1672-7681
    ISSN (online) 2042-0226
    ISSN 1672-7681
    DOI 10.1038/s41423-023-01000-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6681: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Immune modulatory vaccines: time to move into infectious diseases.

    Andersen, Mads Hald

    The Lancet. Microbe

    2022  Volume 4, Issue 1, Page(s) e4–e5

    MeSH term(s) Humans ; Vaccines/therapeutic use ; Communicable Diseases
    Chemical Substances Vaccines
    Language English
    Publishing date 2022-10-26
    Publishing country England
    Document type Journal Article
    ISSN 2666-5247
    ISSN (online) 2666-5247
    DOI 10.1016/S2666-5247(22)00300-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Tumor microenvironment antigens.

    Andersen, Mads Hald

    Seminars in immunopathology

    2022  Volume 45, Issue 2, Page(s) 253–264

    Abstract: The identification and characterization of tumor antigens are central objectives in developing anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered relatively restricted to tumor cells (i.e., overexpressed proteins in ...

    Abstract The identification and characterization of tumor antigens are central objectives in developing anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered relatively restricted to tumor cells (i.e., overexpressed proteins in tumor cells), whereas tumor-specific antigens (TSAs) are considered unique to tumor cells. Recent studies have focused on identifying patient-specific neoantigens, which might be highly immunogenic because they are not expressed in normal tissues. The opposite strategy has emerged with the discovery of anti-regulatory T cells (anti-Tregs) that recognize and attack many cell types in the tumor microenvironment, such as regulatory immune cells, in addition to tumor cells. The term proposed in this review is "tumor microenvironment antigens" (TMAs) to describe the antigens that draw this attack. As therapeutic targets, TMAs offer several advantages that differentiate them from more traditional tumor antigens. Targeting TMAs leads not only to a direct attack on tumor cells but also to modulation of the tumor microenvironment, rendering it immunocompetent and tumor-hostile. Of note, in contrast to TAAs and TSAs, TMAs also are expressed in non-transformed cells with consistent human leukocyte antigen (HLA) expression. Inflammation often induces HLA expression in malignant cells, so that targeting TMAs could additionally affect tumors with no or very low levels of surface HLA expression. This review defines the characteristics, differences, and advantages of TMAs compared with traditional tumor antigens and discusses the use of these antigens in immune modulatory vaccines as an attractive approach to immunotherapy. Different TMAs are expressed by different cells and could be combined in anti-cancer immunotherapies to attack tumor cells directly and modulate local immune cells to create a tumor-hostile microenvironment and inhibit tumor angiogenesis. Immune modulatory vaccines offer an approach for combinatorial therapy with additional immunotherapy including checkpoint blockade, cellular therapy, or traditional cancer vaccines. These combinations would increase the number of patients who can benefit from such therapeutic measures, which all have optimal efficiency in inflamed tumors.
    MeSH term(s) Humans ; Antigens, Neoplasm ; Tumor Microenvironment ; Neoplasms/therapy ; Neoplasms/drug therapy ; Immunotherapy ; T-Lymphocytes, Regulatory ; Cancer Vaccines
    Chemical Substances Antigens, Neoplasm ; Cancer Vaccines
    Language English
    Publishing date 2022-09-29
    Publishing country Germany
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2316828-6
    ISSN 1863-2300 ; 1863-2297
    ISSN (online) 1863-2300
    ISSN 1863-2297
    DOI 10.1007/s00281-022-00966-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1425: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: The targeting of tumor-associated macrophages by vaccination.

    Andersen, Mads Hald

    Cell stress

    2019  Volume 3, Issue 5, Page(s) 139–140

    Abstract: Many different therapeutic strategies focus on targeting tumor-associated macrophages (TAMs), due to their vital role in creating an immune suppressive tumor microenvironment (TME) with the aim to deplete, repro-gram or target the functional mediators ... ...

    Abstract Many different therapeutic strategies focus on targeting tumor-associated macrophages (TAMs), due to their vital role in creating an immune suppressive tumor microenvironment (TME) with the aim to deplete, repro-gram or target the functional mediators secreted by these cells. Immune modulatory vaccination is an emerging strategy to target immune suppressive myeloid populations in the TME. In contrast to the other clinical strategies that target TAMs, this combines both TAM depletion (through direct killing by cytotoxic T cells) and TAM reprogramming (by introducing pro-inflammatory cytokines into the immune suppressive microenvironment).
    Language English
    Publishing date 2019-04-24
    Publishing country Austria
    Document type Journal Article
    ISSN 2523-0204
    ISSN (online) 2523-0204
    DOI 10.15698/cst2019.05.185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens.

    Holmström, Morten Orebo / Andersen, Mads Hald

    Cancers

    2020  Volume 12, Issue 10

    Abstract: ... ...

    Abstract The
    Language English
    Publishing date 2020-10-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12103045
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Anti-cancer immunotherapy: breakthroughs and future strategies.

    Andersen, Mads Hald

    Seminars in immunopathology

    2018  Volume 41, Issue 1, Page(s) 1–3

    MeSH term(s) Biomarkers, Tumor ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Molecular Targeted Therapy ; Neoplasms/etiology ; Neoplasms/immunology ; Neoplasms/therapy
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2018-09-21
    Publishing country Germany
    Document type Editorial
    ZDB-ID 2316828-6
    ISSN 1863-2300 ; 1863-2297
    ISSN (online) 1863-2300
    ISSN 1863-2297
    DOI 10.1007/s00281-018-0711-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1425: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Cancer and autoimmunity.

    Andersen, Mads Hald

    Seminars in immunopathology

    2017  Volume 39, Issue 3, Page(s) 241–243

    MeSH term(s) Autoimmunity ; Humans ; Immune System/physiology ; Myeloid-Derived Suppressor Cells/immunology ; Neoplasms/immunology
    Language English
    Publishing date 2017-03-27
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2316828-6
    ISSN 1863-2300 ; 1863-2297
    ISSN (online) 1863-2300
    ISSN 1863-2297
    DOI 10.1007/s00281-016-0617-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1425: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.

    Strum, Scott / Andersen, Mads Hald / Svane, Inge Marie / Siu, Lillian L / Weber, Jeffrey S

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2024  Volume 44, Issue 3, Page(s) e438592

    Abstract: The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts to generate vaccines against solid and hematologic malignancies using a variety of platforms. To date, these efforts have generally been met with ... ...

    Abstract The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts to generate vaccines against solid and hematologic malignancies using a variety of platforms. To date, these efforts have generally been met with minimal success. However, in the era of improved methods and technological advancements, supported by compelling preclinical and clinical data, a wave of renewed interest in the field offers the promise of discovering field-changing paradigms in the management of established and resected disease using cancer vaccines. These include novel approaches to personalized neoantigen vaccine development, as well as innovative immune-modulatory vaccines (IMVs) that facilitate activation of antiregulatory T cells to limit immunosuppression caused by regulatory immune cells. This article will introduce some of the limitations that have affected cancer vaccine development over the past several decades, followed by an introduction to the latest advancements in neoantigen vaccine and IMV therapy, and then conclude with a discussion of some of the newest technologies and progress that are occurring across the cancer vaccine space. Cancer vaccines are among the most promising frontiers for breakthrough innovations and strategies poised to make a measurable impact in the ongoing fight against cancer.
    MeSH term(s) Humans ; Cancer Vaccines/therapeutic use ; Neoplasms/immunology ; Neoplasms/therapy ; Biomarkers, Tumor ; Antigens, Neoplasm/immunology ; Immunotherapy/methods
    Chemical Substances Cancer Vaccines ; Biomarkers, Tumor ; Antigens, Neoplasm
    Language English
    Publishing date 2024-04-26
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.1200/EDBK_438592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.

    Glöckner, Hannah Jorinde / Martinenaite, Evelina / Landkildehus Lisle, Thomas / Grauslund, Jacob / Ahmad, Shamaila / Met, Özcan / Thor Straten, Per / Hald Andersen, Mads

    Oncoimmunology

    2024  Volume 13, Issue 1, Page(s) 2318053

    Abstract: Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have been observed in both healthy individuals and ... ...

    Abstract Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have been observed in both healthy individuals and cancer patients. However, while the function of anti-regulatory Arg1-specific CD4+ T cells has been characterized, our knowledge of CD8+ Arg1-specific T cells is only scarce. In the current study, we describe the immune-modulatory capabilities of CD8+ Arg1-specific T cells. We generated CD8+ Arg1-specific T cell clones to target Arg1-expressing myeloid cells. Our results demonstrate that these T cells recognize both malignant and nonmalignant regulatory myeloid cells in an Arg1-expression-dependent manner. Notably, Arg1-specific CD8+ T cells possess cytolytic effector capabilities. Immune modulatory vaccines (IMVs) represent a novel treatment modality for cancer. The activation of Arg1-specific CD8+ T cells through Arg1-based IMVs can contribute to the modulatory effects of this treatment strategy.
    MeSH term(s) Humans ; Arginase ; CD8-Positive T-Lymphocytes ; Myeloid Cells ; Neoplasms/therapy ; Tumor Microenvironment
    Chemical Substances Arginase (EC 3.5.3.1)
    Language English
    Publishing date 2024-02-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2645309-5
    ISSN 2162-402X ; 2162-402X
    ISSN (online) 2162-402X
    ISSN 2162-402X
    DOI 10.1080/2162402X.2024.2318053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top